Where I Work

I run the operations at Quintessence Biosciences, a clinical stage biopharmaceutical company focused on development of proprietary cancer therapies. We licensed technology from the UW Madison (WARF) and the company has advanced the EVade™ Ribonucleases (RNases), from discovery to clinical.

Our technology allows for the attack of the RNA inside cancer cells and the EVade™ RNases have shown broad efficacy in model systems, including tumor growth inhibition against breast, colon, non-small cell lung, pancreatic and prostate cancers. Our first drug, QBI- 139, is in a Phase 1 clinical trial at The University of Texas MD Anderson Cancer Center and The University of Wisconsin Carbone Cancer Center.

While a frog RNase has been in clinical trials (Onconase from Tamir Biotechnology), QBI-139 appears to be significantly differentiated by the therapeutic window seen in in vivo model systems and the clinic. While the Phase II/III dose of Onconase was 0.48 mg/m², the most recent (March 2012) dose in the Phase I study of QBI-139 was 67 mg/m².

In addition to development work for the next stage of clinical trials, we are pursuing additional products from our EVade™  RNase technology. To date, we have raised approximately $16.5M from individual investors.

Our goal is to provide a positive new treatment option for patients while also ensuring a return for shareholders.